Carregant...
Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided
AIMS: We assessed the potential mutual interaction of oral macitentan (cytochrome P450 (CYP) 3A4 substrate) at steady‐state with single‐dose oral rivaroxaban (CYP3A4 and P‐glycoprotein substrate) and evaluated the effect of the CYP3A and P‐glycoprotein inducer St John's wort (SJW) on the pharma...
Guardat en:
| Publicat a: | Br J Clin Pharmacol |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6255992/ https://ncbi.nlm.nih.gov/pubmed/30192025 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13757 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|